2023 World Conference on Lung Cancer (Posters)-P2.11. SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation

P2.11. SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation - PDF(Slides)

Back to course

Pdf Summary

The SHERLOCK trial aims to evaluate the effectiveness and safety of upfront sotorasib, a selective, irreversible KRASG12C inhibitor, in combination with carboplatin-pemetrexed chemotherapy and bevacizumab-biosimilar in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) with KRASG12C mutation. The primary objective of the trial is to assess the objective response rate (ORR) according to RECIST 1.1 criteria. Secondary objectives include measuring progression-free survival, duration of response, depth of response, overall survival, and monitoring adverse events. The trial also aims to investigate the potential prognostic biomarkers associated with clinical outcomes.<br /><br />The trial is a phase II, single arm, open-label, multicenter study conducted in Australia with a total of 52 participants. Eligible participants include adults aged 18 and above with the KRASG12C mutation and newly diagnosed metastatic non-squamous NSCLC or recurrent disease without progression for at least 6 months after prior treatment. They must also have measurable disease according to RECIST 1.1 criteria and an ECOG performance status of 0 or 1.<br /><br />Sotorasib has previously shown promising results in clinical trials, with a decrease in the relative risk of disease progression or death and a superior objective response rate compared to docetaxel in previously treated advanced NSCLC. However, resistance mechanisms associated with sotorasib are diverse, leading to the investigation of combination treatment strategies.<br /><br />The SHERLOCK trial acknowledges the contribution of participants and their carers, as well as the investigators and study coordinators at participating sites. The trial is a collaboration between the Thoracic Oncology Group of Australasia (TOGA) and the NHMRC Clinical Trials Centre (NHMRC CTC) at the University of Sydney, with financial support from AMGEN.<br /><br />For more information about the SHERLOCK trial, interested individuals can email sherlock.study@sydney.edu.au or visit the TOGA website at www.thoraciconcology.org.au. The trial is registered with the clinical trial identifier ACTRN12622000973718. Participating sites include various hospitals and cancer centers in New South Wales, South Australia, Victoria, Queensland, and Tasmania.

Asset Subtitle

Chee Lee

Meta Tag

Speaker Chee Lee

Topic Metastatic NSCLC: Targeted Therapy - KRAS/MET

Keywords

SHERLOCK trial

sotorasib

KRASG12C inhibitor

NSCLC

objective response rate

RECIST 1.1 criteria

progression-free survival

prognostic biomarkers

clinical trials

combination treatment strategies